There is a great need in the neurological disorders field to identify novel surrogate biomarkers that can help assess injury severity in patients with severe CNS injury.  Biomarker discovery is a fast growing field, and many candidate markers of injury have been identified, some of which being selective to the CNS.  InflamaCORE has recently identified several inflammasome proteins that can help identify abnormal activation of the innate immune response that is believed to lead to downstream inflammasome processes and secondary injury mechanisms.  Recent publications indicate that levels of circulating inflammasome proteins are correlated with behavioral outcomes in patients with severe TBI.  These new technologies in combination with the development of novel antibodies directed against inflammasome components represent a powerful approach by which to treat and evaluate innovative therapies targeting neurotrauma.